Published in Drug Week, September 8th, 2006
In a recent report, researchers in the United States conducted a study "to determine the maximum tolerated dose, dose-limiting toxicities, and pharmacokinetic characteristics of doxorubicin encapsulated in a LTSL when given concurrently with local hyperthermia to canine solid tumors. Privately owned dogs with solid tumors (carcinomas or sarcomas) were treated. The tumors did not involve bone and were located at sites amenable to local hyperthermia."
M.L. Hauck and colleagues, North Carolina State University, wrote,...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week